Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icenticaftor Mode of Action Study in COPD
NCT04268823Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QBW251 with Placebo (2 arms). Primary endpoint: Change From Baseline in Fibrinogen Plasma Concentrations at 12 weeks. Started Sep 2020; status: terminated.
02
Drugs
Icenticaftor
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04268823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268823.